Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) COO Liane Rae Teplitsky bought 1,034 shares of the stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average price of $48.35 per share, with a total value of $49,993.90. Following the completion of the acquisition, the chief operating officer directly owned 2,070 shares in the company, valued at $100,084.50. This trade represents a 99.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Liane Rae Teplitsky also recently made the following trade(s):
- On Wednesday, August 26th, Liane Rae Teplitsky bought 1,036 shares of Pulse Biosciences stock. The stock was purchased at an average cost of $48.23 per share, with a total value of $49,966.28.
Pulse Biosciences Stock Down 2.0%
NASDAQ:PLSE traded down $0.99 on Friday, reaching $47.57. 262,703 shares of the company’s stock were exchanged, compared to its average volume of 406,808. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. Pulse Biosciences, Inc has a 52-week low of $12.56 and a 52-week high of $50.90. The business has a fifty day moving average of $35.38 and a 200-day moving average of $27.00.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Pulse Biosciences during the second quarter worth approximately $40,672,000. Bank of America Corp DE acquired a new position in Pulse Biosciences during the 2nd quarter worth approximately $40,115,000. California State Teachers Retirement System grew its holdings in Pulse Biosciences by 2,600.0% during the 2nd quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after acquiring an additional 546,850 shares in the last quarter. State Street Corp increased its position in shares of Pulse Biosciences by 6.0% in the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock valued at $6,138,000 after purchasing an additional 25,187 shares during the last quarter. Finally, Brooklyn Investment Group increased its position in shares of Pulse Biosciences by 330.7% in the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock valued at $1,844,000 after purchasing an additional 100,081 shares during the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Canaccord Genuity Group upped their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Needham & Company LLC started coverage on Pulse Biosciences in a research report on Monday, August 17th. They set a “buy” rating and a $58.00 price objective on the stock. Finally, Wall Street Zen cut Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulse Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.
Check Out Our Latest Research Report on PLSE
About Pulse Biosciences
Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.
Read More
- Five stocks we like better than Pulse Biosciences
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
